Decitabine: A review of its use in older patients with acute myeloid leukaemia

Drugs and Aging

Volumn 30, Issue 6, 2013, Pages 447-458

  Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYTARABINE; INFUSION FLUID;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ENTERIC FEEDING; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; GERIATRICS; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARENTERAL NUTRITION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SINUSITIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZACITIDINE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EUROPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84878628126     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0084-x     Document Type: Review

References (60)

1. Villela L, Bolanos-Meade J. Acute myeloid leukaemia: optimal management of acute myeloid leukaemia and recent developments. Drugs. 2011;71(2):1537-50.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
3. National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. 2012. http://seer.cancer.gov/statfacts/html/amyl.html. Accessed 20 Dec 2012.
4. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v158-61.
5. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
6. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524-42.
7. O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10(8):984-1021.
8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.
9. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597-603.
10. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;72(8):1111-36.
11. Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46(11):1511-7.
12. Baylin SB, Fearon ER, Vogelstein B, et al. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood. 1987;70(2):412-7.
13. Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26(2):244-54.
14. Pliml J, Sorm K. Synthesis of 2'-deoxy-d-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun. 1964;29:2576-7.
15. McKeage K, Croom KF. Decitabine: in myelodysplastic syndromes. Drugs. 2006;66(7):951-8.
16. European Medicines Agency. Dacogen (decitabine): summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002221/WC500133569.pdf. Accessed 8 Feb 2013.
17. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE. 2 Feb 2010. doi: 10.1371/journal.pone.0009001.
18. Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120(12):2466-74.
19. Soncini M, Santoro F, Gutierrez A, et al. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta. 2013;1832(1):114-20.
20. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-46.
21. Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121(9):1633-43.
22. Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010;7(8):433-44.
23. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019-28.
24. Lund P, Kotova I, Kedinger V, et al. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther. 2011;10(9):1611-23.
25. Pinto A, Attadia V, Fusco A, et al. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984;64(4):922-9.
26. Momparler RL. Pharmacology of 5-aza-2'-deoxycytidine (decitabine). Semin Hematol. 2005;42(Suppl. 2):S9-16.
27. Weiser TS, Ohnmacht GA, Guo ZS, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg. 2001;71(1):295-301.
28. Sigalotti L, Altomonte M, Colizzi F, et al. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood. 2003;101(11):4644-6.
29. Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood. 2009;113(3):659-67.
30. Vesely J, Cihak A. Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice. Cancer Res. 1977;37(10):3684-9.
31. Colombo T, Rossi C, D'Incalci M. Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine. Cancer Treat Rep. 1986;70(12):1451-3.
32. Richel DJ, Colly LP, Lurvink E, et al. Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer. 1988;58(6):730-3.
33. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5):1106-7.
34. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-8.
35. Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012;26(11):2428-31.
36. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393-401.
37. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-91.
38. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-7.
39. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-61.
40. European Medicines Agency. Dacogen: European public assessment report. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002221/WC500133571.pdf. Accessed 12 Feb 2013.
41. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-9.
42. Thomas X, Arthur C, Delaunay J, et al. A post hoc landmark analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia [abstract no. 3623]. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA; 8-11 Dec 2012.
43. Mayer J, Arthur C, Delaunay J, et al. Multivariate and subgroup analyses of a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia [abstract no. 3618]. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA; 8-11 Dec 2012.
44. Dass RN, Howes A, Spencer M, et al. Decitabine reduces transfusion dependence in older patients with acute myeloid leukaemia: results from a post-hoc analysis of a randomised phase III trial. Value Health. 2012;15(7):A431.
45. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135(4):450-74.
46. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol. 2012;96(2):186-93.
47. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690-5.
48. European Medicines Agency. Committee for Medicinal Products for Human Use summary of opinion for dacogen (decitabine). 2012. http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/ 002221/WC500130136.pdf. Accessed 12 Feb 2013.
49. ® in acute myeloid leukemia [media release]. 10 Feb 2012. http://www.eisai.com/pdf/others/e20120210.pdf.
50. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115:5746-51.
51. Ornstein MC, Sekeres MA. Combination strategies in myelodysplastic syndromes. Int J Hematol. 2012;95(1):26-33.
52. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-9.
53. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025-31.
54. Welch JS, Klco JM, Gao F, et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9):796-800.
55. Klimek V, Dolezal EK, Juric JG, et al. Phase 2 study of decitabine in combination with tretinoin in myelodysplastic syndromes and acute myelogenous leukemia: interim results [abstract no. 3815]. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA; 8-11 Dec 2012.
56. Daver N, Kantarjian HM, Garcia-Manero G, et al. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome [abstract no. 3619]. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA; 8-11 Dec 2012.
57. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 7 Feb 2013. doi: 10.3109/10428194.2012.762093.
58. Ganguly S, Amin M, Divine C, et al. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann Hematol. 2013;92(4):549-50.
59. Lubbert M, Bertz H, Ruter B, et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44:585-8.
60. Ustun C, Kalla A, Farrow S, et al. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol. 2008;83(10):825-7.